Mexico Liver Cancer Therapeutics Market Report 2022 to 2030

Mexico Liver Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Mexico Liver Cancer Therapeutics market will reach a value of $163.5 Mn from $44 Mn in 2022, growing at a CAGR of 17.9 % during 2022-2030. Liver Cancer Therapeutics in Mexico is dominated by a few domestic pharmaceutical companies such as Laboratorios PiSA, Liomont and Genomma Lab Internacional. The Liver Cancer Therapeutics market in Mexico is segmented into different types of cancer and different therapy type. Some of the major factors affecting the Mexico Liver Cancer Therapeutics market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.

ID: IN10MXPH039 CATEGORY: Pharmaceuticals GEOGRAPHY: Mexico AUTHOR: Dr. Vishwa Modhia

Buy Now

Mexico Liver Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the Mexico Liver Cancer Therapeutics market will reach a value of $163.5 Mn from $44 Mn in 2022, growing at a CAGR of 17.9 % during 2022-2030.

Mexico is an upper middle-income, developing country located in North America with a North Pacific Ocean, Gulf of Mexico, and Caribbean Sea coastline. The main risk factors for liver cancer in Mexico are chronic hepatitis B and C virus infections, alcohol abuse, obesity, and type 2 diabetes. The most used therapies for liver cancer in Mexico include surgery, liver transplantation, and chemotherapy.

According to the latest WHO data published in 2020 Liver Cancer Deaths in Mexico reached 6,817 or 1.10% of total deaths. About 21% of the estimated cancers in Mexico, were liver cancers attributed to alcohol drinking. The age-adjusted Death Rate is 5.75 per 100,000 of population ranks Mexico 84^th in the world. Mexico's government spent 6.2 % of its GDP on healthcare in 2020.

Mexico Liver Cancer Therapeutics Analysis

Market Dynamics

Market Growth Drivers Analysis

The Mexican government has launched several programmes, notably the National Cancer Institute and the Cancer Prevention and Control Program, to enhance the prevention, detection, and treatment of liver cancer in the country. Immunotherapy medicines such as nivolumab and pembrolizumab have been approved in other countries for the treatment of liver cancer but are not currently available in Mexico. With an estimated 7,500 new cases identified each year, Mexico has one of the highest incidence rates of liver cancer in the world. Mexico has a vast population, is geographically close to the American economy, and has a low labour cost. These aspects could boost Mexico's Liver Cancer Therapeutics market.

Market Restraints

While there have been advances in the treatment of liver cancer, individuals in Mexico still have few options, particularly those with advanced diseases. This can reduce therapy effectiveness and lead to poorer outcomes. Mexico has a considerable economic disparity, a high level of informality in the labour sector, and rising criminality. These factors may deter new entrants into the Mexico Liver Cancer Therapeutics market.

Competitive Landscape

Key Players

Laboratorios PiSA: One of the largest pharmaceutical companies in Mexico, Laboratorios PiSA has a strong presence in the oncology therapeutics market. The company offers a range of oncology products, including chemotherapy drugs, supportive care products, and biosimilars
Liomont: Liomont is a Mexican pharmaceutical company that specializes in the development and manufacturing of biotech products, including oncology therapeutics
Silanes Laboratories: Silanes Laboratories is a Mexican pharmaceutical company that develops and markets a range of oncology products, including chemotherapy drugs, supportive care products, and biosimilars
Genomma Lab Internacional: Genomma Lab is a Mexican pharmaceutical company that develops and markets a range of healthcare products, including oncology therapeutics
Landsteiner Scientific: Landsteiner Scientific is a Mexican biopharmaceutical company that specializes in the development and commercialization of oncology therapeutics

Healthcare Policies and Reimbursement Scenarios

The regulation and reimbursement of liver cancer therapeutics in Mexico are overseen by the Federal Commission for Protection against Sanitary Risk (COFEPRIS) and the Mexican Institute of Social Security (IMSS), respectively. COFEPRIS is responsible for regulating the safety, quality, and efficacy of pharmaceuticals in Mexico. The reimbursement of liver cancer therapeutics in Mexico is primarily covered by IMSS, which is the largest public healthcare institution in the country. IMSS provides healthcare services to employees of private companies, as well as their dependents.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Liver Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Hepatocellular Carcinoma
Cholangio Carcinoma
Hepatoblastoma
Other Types

By Treatment (Revenue, USD Billion):

Chemotherapy
Immunotherapy
Targeted Therapy
Radiation Therapy
Ablation Therapy
Embolization Therapy

By Equipment (Revenue, USD Billion):

Computed Radiography
MRI
Sonography
Others

By Route of Administration (Revenue, USD Billion):

Oral
Intravenous

By End User (Revenue, USD Billion):

Hospitals
Clinics
Ambulatory Surgical Centers

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.